{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:52:51Z","timestamp":1788911571864,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12325-025-03411-4","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:10:49Z","timestamp":1763737849000},"page":"271-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Complications, Mortality, and Healthcare Resource Utilization of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Ontario, Canada: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4044-269X","authenticated-orcid":false,"given":"Lauren","family":"Lilly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuka","family":"Udeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Nightingale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Penaranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calum S.","family":"Neish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin H. M.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"3411_CR1","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.","journal-title":"Nat Rev Dis Primers"},{"key":"3411_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","volume":"14","author":"P Sundd","year":"2019","unstructured":"Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019;14:263\u201392.","journal-title":"Annu Rev Pathol"},{"issue":"10091","key":"3411_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","volume":"390","author":"RE Ware","year":"2017","unstructured":"Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311\u201323.","journal-title":"Lancet"},{"issue":"3","key":"3411_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13430","volume":"105","author":"DS Darbari","year":"2020","unstructured":"Darbari DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management. Eur J Haematol. 2020;105(3):237\u201346.","journal-title":"Eur J Haematol"},{"issue":"3","key":"3411_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.7861\/clinmed.2022-0143","volume":"22","author":"E Conway O'Brien","year":"2022","unstructured":"Conway O\u2019Brien E, Ali S, Chevassut T. Sickle cell disease: an update. Clin Med. 2022;22(3):218\u201320.","journal-title":"Clin Med"},{"issue":"6","key":"3411_CR6","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s11136-019-02412-5","volume":"29","author":"AA Rizio","year":"2020","unstructured":"Rizio AA, Bhor M, Lin X, et al. The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease. Qual Life Res. 2020;29(6):1533\u201347.","journal-title":"Qual Life Res"},{"issue":"1","key":"3411_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ajh.20336","volume":"79","author":"SK Ballas","year":"2005","unstructured":"Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79(1):17\u201325.","journal-title":"Am J Hematol"},{"issue":"23","key":"3411_CR8","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","volume":"330","author":"OS Platt","year":"1994","unstructured":"Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639\u201344.","journal-title":"N Engl J Med"},{"issue":"11","key":"3411_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079923","volume":"8","author":"DS Darbari","year":"2013","unstructured":"Darbari DS, Wang Z, Kwak M, et al. Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. PLoS ONE. 2013;8(11):e79923.","journal-title":"PLoS ONE"},{"issue":"12","key":"3411_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28698","volume":"67","author":"ME Roman","year":"2020","unstructured":"Roman ME, Highland J, Retherford D, Pan AY, Panepinto JA, Brandow AM. Neuropathic pain is associated with poor health-related quality of life in adolescents with sickle cell disease: a preliminary report. Pediatr Blood Cancer. 2020;67(12):e28698.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"3411_CR11","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","volume":"4","author":"AM Brandow","year":"2020","unstructured":"Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656\u2013701.","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"3411_CR12","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1182\/blood-2019-128700","volume":"134","author":"L Bront\u00e9-Hall","year":"2019","unstructured":"Bront\u00e9-Hall L, Parkin M, Green C, et al. Real-world clinical burden of sickle cell disease in the US community-practice setting: a single-center experience from the Foundation for Sickle Cell Disease Research. Blood. 2019;134(Supplement_1):5856.","journal-title":"Blood"},{"issue":"9","key":"3411_CR13","first-page":"2476","volume":"108","author":"V Brousse","year":"2023","unstructured":"Brousse V, Bernaudin F, Melaine A, et al. Severity and burden of sickle cell disease in France: a nationwide real-world study. Haematologica. 2023;108(9):2476\u201386.","journal-title":"Haematologica"},{"issue":"1","key":"3411_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/jcm12010117","volume":"12","author":"L De Franceschi","year":"2022","unstructured":"De Franceschi L, Castiglioni C, Condorelli C, et al. Real-world evidence on disease burden and economic impact of sickle cell disease in Italy. J Clin Med. 2022;12(1):117.","journal-title":"J Clin Med"},{"issue":"3","key":"3411_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1182\/bloodadvances.2021006281","volume":"7","author":"KM Johnson","year":"2023","unstructured":"Johnson KM, Jiao B, Ramsey SD, Bender MA, Devine B, Basu A. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Adv. 2023;7(3):365\u201374.","journal-title":"Blood Adv"},{"issue":"7","key":"3411_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214355","volume":"14","author":"N Shah","year":"2019","unstructured":"Shah N, Bhor M, Xie L, Paulose J, Yuce H. Sickle cell disease complications: prevalence and resource utilization. PLoS ONE. 2019;14(7):e0214355.","journal-title":"PLoS ONE"},{"issue":"4","key":"3411_CR17","doi-asserted-by":"publisher","first-page":"E725","DOI":"10.9778\/cmajo.20220145","volume":"11","author":"J Pendergrast","year":"2023","unstructured":"Pendergrast J, Ajayi LT, Kim E, Campitelli MA, Graves E. Sickle cell disease in Ontario, Canada: an epidemiologic profile based on health administrative data. CMAJ Open. 2023;11(4):E725\u201333.","journal-title":"CMAJ Open"},{"issue":"12","key":"3411_CR18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1080\/03007995.2024.2421287","volume":"40","author":"J Baldwin","year":"2024","unstructured":"Baldwin J, Udeze C, Li N, et al. Clinical burden and healthcare resource utilization associated with managing sickle cell disease with recurrent vaso-occlusive crises in France. Curr Med Res Opin. 2024;40(12):2117\u201324.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"3411_CR19","first-page":"S2","volume":"27","author":"J Drahos","year":"2024","unstructured":"Drahos J, Peres F, Reimes N, et al. Healthcare resource utilization among patients with sickle cell disease with recurrent vaso-occlusive crises in the Netherlands. Value in Health. 2024;27(12):S2.","journal-title":"Value in Health"},{"issue":"6","key":"3411_CR20","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1016\/j.jval.2023.03.705","volume":"26","author":"C Udeze","year":"2023","unstructured":"Udeze C, Dovizio M, Veronesi C, et al. EE404 healthcare resource utilization among patients with sickle cell disease with recurrent vaso-occlusive crises in Italy. Value Health. 2023;26(6):S133.","journal-title":"Value Health"},{"issue":"8","key":"3411_CR21","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1007\/s12325-023-02545-7","volume":"40","author":"C Udeze","year":"2023","unstructured":"Udeze C, Evans KA, Yang Y, et al. Economic and clinical burden of managing sickle cell disease with recurrent vaso-occlusive crises in the United States. Adv Ther. 2023;40(8):3543\u201358.","journal-title":"Adv Ther"},{"issue":"2","key":"3411_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s41669-024-00550-2","volume":"9","author":"C Udeze","year":"2025","unstructured":"Udeze C, Li N, Kunzweiler C, et al. Clinical complications and healthcare resource utilization associated with conventional management of sickle cell disease with recurrent vaso-occlusive crises and transfusion-dependent beta-thalassemia in Germany. Pharmacoecon Open. 2025;9(2):291\u2013300.","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"3411_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.clinthera.2024.09.023","volume":"47","author":"C Udeze","year":"2025","unstructured":"Udeze C, Ly NF, Ingleby FC, et al. Clinical burden and health care resource utilization associated with managing sickle cell disease with recurrent vaso-occlusive crises in England. Clin Ther. 2025;47(1):29\u201336.","journal-title":"Clin Ther"},{"issue":"2","key":"3411_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4103\/ajts.AJTS_71_16","volume":"14","author":"DC Sharma","year":"2020","unstructured":"Sharma DC, Singhal S, Woike P, Rai S, Yadav M, Gaur R. Hereditary persistence of fetal hemoglobin. Asian J Transfus Sci. 2020;14(2):185\u20136.","journal-title":"Asian J Transfus Sci"},{"issue":"4 Suppl","key":"3411_CR25","doi-asserted-by":"publisher","first-page":"S528","DOI":"10.1016\/j.amepre.2010.01.003","volume":"38","author":"SL Boulet","year":"2010","unstructured":"Boulet SL, Yanni EA, Creary MS, Olney RS. Health status and healthcare use in a national sample of children with sickle cell disease. Am J Prev Med. 2010;38(4 Suppl):S528\u201335.","journal-title":"Am J Prev Med"},{"issue":"12","key":"3411_CR26","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jval.2023.09.260","volume":"26","author":"J Baldwin","year":"2023","unstructured":"Baldwin J, Udeze C, Li N, et al. CO188 mortality and clinical complications among patients with sickle cell disease with recurrent vaso-occlusive crises in France. Value Health. 2023;26(12):S47.","journal-title":"Value Health"},{"issue":"3","key":"3411_CR27","doi-asserted-by":"publisher","first-page":"576078","DOI":"10.1097\/01.HS9.0000976744.57607.c8","volume":"7","author":"C Udeze","year":"2023","unstructured":"Udeze C, Kunzweiler C, Li N, et al. PB2511: clinical complications among patients with sickle cell disease with recurrent vaso-occlusive crises in Germany. Hemasphere. 2023;7(3):576078.","journal-title":"Hemasphere."},{"issue":"1","key":"3411_CR28","first-page":"31","volume":"201","author":"CL Udeze","year":"2023","unstructured":"Udeze CL, Fleming SD, Conner S, Howard J, Li N, Shah F. Mortality and clinical complications among patients with sickle cell disease with recurrent vaso-occlusive crises in england. Brit J Haematol. 2023;201(1):31\u2013118.","journal-title":"Brit J Haematol"},{"key":"3411_CR29","doi-asserted-by":"crossref","unstructured":"Udeze CL, Ingleby FC, Fleming SD, Conner, S, Howard J, Li N, Shah F. 2023 PO110: Mortality and Clinical Complications Among Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in England. British Society for Haematology","DOI":"10.1016\/j.jval.2023.03.2507"},{"issue":"3","key":"3411_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.36469\/9667","volume":"6","author":"N Shah","year":"2019","unstructured":"Shah N, Bhor M, Xie L, et al. Evaluation of vaso-occlusive crises in United States sickle cell disease patients: a retrospective claims-based study. J Health Econom Outcomes Res. 2019;6(3):106\u201317.","journal-title":"J Health Econom Outcomes Res"},{"issue":"4","key":"3411_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0297469","volume":"19","author":"A Singh","year":"2024","unstructured":"Singh A, Brousseau DC, Dasgupta M, Shet AS, Field JJ, Brandow AM. Acute care utilization among individuals with sickle cell disease and related cardiopulmonary and renal complications. PLoS ONE. 2024;19(4):e0297469.","journal-title":"PLoS ONE"},{"issue":"11","key":"3411_CR32","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1007\/s00277-020-04205-0","volume":"99","author":"SK Ballas","year":"2020","unstructured":"Ballas SK, Dampier C. Risk factors associated with increased emergency department utilization in patients with sickle cell disease: a systematic literature review. Ann Hematol. 2020;99(11):2483\u201395.","journal-title":"Ann Hematol"},{"issue":"12","key":"3411_CR33","volume":"13","author":"AK Kvam","year":"2021","unstructured":"Kvam AK, Torp HA, Iversen PO. Life-threatening acute chest syndrome in a patient with sickle cell disease after switching from hydroxyurea therapy to partial exchange transfusions: a case report. Cureus. 2021;13(12):e20236.","journal-title":"Cureus"},{"issue":"4","key":"3411_CR34","volume":"4","author":"SJ Nevitt","year":"2017","unstructured":"Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2017;4(4):CD002202.","journal-title":"Cochrane Database Syst Rev"},{"key":"3411_CR35","unstructured":"Pr: Mylan Pharmaceuticals ULC, 2023."},{"issue":"3","key":"3411_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1586\/ehm.10.22","volume":"3","author":"AM Brandow","year":"2010","unstructured":"Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol. 2010;3(3):255\u201360.","journal-title":"Expert Rev Hematol"},{"issue":"18","key":"3411_CR37","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/bloodadvances.2020001701","volume":"4","author":"JR Hodges","year":"2020","unstructured":"Hodges JR, Phillips SM, Norell S, et al. Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study. Blood Adv. 2020;4(18):4463\u201373.","journal-title":"Blood Adv"},{"issue":"4","key":"3411_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.5001\/omj.2019.64","volume":"34","author":"J Jose","year":"2019","unstructured":"Jose J, Elsadek RA, Jimmy B, George P. Hydroxyurea: pattern of use, patient adherence, and safety profile in patients with sickle cell disease in Oman. Oman Med J. 2019;34(4):327\u201335.","journal-title":"Oman Med J"},{"issue":"8","key":"3411_CR39","first-page":"968","volume":"100","author":"S Lanzkron","year":"2008","unstructured":"Lanzkron S, Haywood C Jr., Hassell KL, Rand C. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc. 2008;100(8):968\u201373.","journal-title":"J Natl Med Assoc"},{"key":"3411_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60010124","author":"MA Madkhali","year":"2024","unstructured":"Madkhali MA, Abusageah F, Hakami F, et al. Adherence to hydroxyurea and patients\u2019 perceptions of sickle cell disease and hydroxyurea: a cross-sectional study. Medicina (Kaunas). 2024. https:\/\/doi.org\/10.3390\/medicina60010124.","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"3411_CR41","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/jha2.575","volume":"3","author":"D Manwani","year":"2022","unstructured":"Manwani D, Burnett AL, Paulose J, et al. Treatment patterns and burden of complications associated with sickle cell disease: a US retrospective claims analysis. EJHaem. 2022;3(4):1135\u201344.","journal-title":"EJHaem"},{"issue":"9","key":"3411_CR42","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/pds.4860","volume":"28","author":"ZT Su","year":"2019","unstructured":"Su ZT, Segal JB, Lanzkron S, Ogunsile FJ. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997\u20132017. Pharmacoepidemiol Drug Saf. 2019;28(9):1246\u201350.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3411_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.921432","volume":"13","author":"MJ Treadwell","year":"2022","unstructured":"Treadwell MJ, Du L, Bhasin N, et al. Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: report from a U.S. regional collaborative. Front Genet. 2022;13:921432.","journal-title":"Front Genet"},{"issue":"11","key":"3411_CR44","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/ajh.24498","volume":"91","author":"J Han","year":"2016","unstructured":"Han J, Saraf SL, Zhang X, et al. Patterns of opioid use in sickle cell disease. Am J Hematol. 2016;91(11):1102\u20136.","journal-title":"Am J Hematol"},{"issue":"5","key":"3411_CR45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/pds.4291","volume":"27","author":"J Han","year":"2018","unstructured":"Han J, Zhou J, Saraf SL, Gordeuk VR, Calip GS. Characterization of opioid use in sickle cell disease. Pharmacoepidemiol Drug Saf. 2018;27(5):479\u201386.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"3411_CR46","first-page":"94","volume":"7","author":"HA Kang","year":"2020","unstructured":"Kang HA, Barner JC, Richards KM, Bhor M, Paulose J, Kutlar A. Association between vaso-occlusive crises and opioid prescriptions among patients with sickle cell disease: a retrospective claims-based study. J Health Econ Outcomes Res. 2020;7(1):94\u2013101.","journal-title":"J Health Econ Outcomes Res"},{"key":"3411_CR47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124920","author":"G Joseph","year":"2019","unstructured":"Joseph G, Latremouille-Viau D, Sharma V, et al. Vaso-occlusive crises and costs of sickle cell disease from a commercial payer\u2019s perspective. Blood. 2019. https:\/\/doi.org\/10.1182\/blood-2019-124920.","journal-title":"Blood"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03411-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03411-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03411-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:02:57Z","timestamp":1769770977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03411-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3411"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03411-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lauren Lilly, Chuka Udeze, Carlos Penaranda, and Nanxin Li are employees of Vertex Pharmaceuticals Incorporated and may own stock or stock options in the company. Natalie Nightingale, Irene Wang, Jillian Murphy, and Calum S. Neish are consultants from IQVIA, who were paid contractors to Vertex Pharmaceutical Incorporated in this study. Kevin H.M. Kuo is now affiliated with Scarborough Health Network Research Institute; Toronto, Ontario, CA. He discloses consultancy work for Agios Pharmaceuticals, Alexion Pharmaceuticals, Biossil Inc, Bristol-Myers Squibb, Novo Nordisk, Pfizer Inc, and Vertex Pharmaceuticals; has received research funding from Agios Pharmaceuticals and Pfizer Inc; and holds membership on a Board or Advisory Committee at Bioverativ\/Sanofi\/Sangamo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study contracted ICES Data & Analytic Services (DAS) and used de-identified data from the ICES Data Repository, managed by ICES with support from its funders and partners: Canada\u2019s Strategy for Patient-Oriented Research (SPOR), the Ontario SPOR Support Unit, the Canadian Institutes of Health Research, and the Government of Ontario.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This study used de-identified data from the ICES Data Repository. The authors do not own the data. Data are owned by ICES, and we do not have access to raw data. As such, it has not been made available on a public site. Raw outputs will be on the ICES website per the agreement with ICES. Requests for data can be made to the ICES Data Repository.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}}]}}